Triple-drug regimen lowers A1C, treatment failure in new-onset diabetes

10/8/2013 | InternalMedicineNews.com (free registration)

Patients with new-onset type 2 diabetes who had initial triple-drug treatment of metformin, exenatide and pioglitazone attained a mean A1C of 5.9% at two years, compared with 6.6% in those who received conventional stepwise treatment, a study indicated. Researchers also found the triple-drug regimen was associated with an 84% reduction in two-year treatment failure rates compared with standard therapy. The results were presented at the European Association for the Study of Diabetes meeting.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY